A triphasic oral contraceptive unit having 21 separate dosage units, adapted for successive daily oral administration, comprising:5-8 dosage units containing, separately or in admixture, a combination of an estrogen and progestogen at contraceptively effective dosages corresponding in estrogenic activity to 25 g of 17 -ethinylestradiol and in progestogenic activity to 0.180 mg of norgestimate as a first phase; followed by 7-11 dosage units containing, separately or in admixture, a combination of an estrogen and a progestagen at a contracepttvely effective dosage corresponding in estrogenic activity to 25 g of 17 a ethinylestradiol and in progestogenic activity to 0.215 mg of norgestimate as a second phase; followed by 3-7 dosage units containing separately or in admixture a combination of an estogen and a progestagen at a contraceptive effective dosages corresponding in estogenic activity to 25 g of 17a ethinylestrodiol and in progrestogenic activity to 0.250 mg of norgestimate as a third phase; and optionally containing 4-8 additional dosages units free of estogen and progestogen; with the provisos that the progestogen dose should increase from the first phase to the second phase to the third phase and that the dosage of estogen is kept constant in each phase.
展开▼
